Improving Patient
Outcomes in
Solid Tumor
Cancer TreatmentBIO300
A New Class of Cancer Drug
Keeping America Safe
BIO300
Protecting Civilians, First Responders and Our Military
from Nuclear Accidents and Terrorism
Humanetics News
05.28.20
Humanetics Corporation Invited for Oral Presentation at Annual Meeting of American Society of Radiation Oncologists
Read More
05.06.20
Dr. Colin Chinn, Former Staff Surgeon, Joins Medical Advisory Board
Read More
02.19.20
Humanetics Acquires Manufacturing Assets for Radioprotectant Drug
Read More
10.01.19
Humanetics Received New $6 Million Contract from Department of Defense
Read More
10.23.18
Humanetics Corporation to Present at Annual Meeting of Society for Radiation Oncology
Read More
10.8.18
Humanetics Corporation Invited to Present Data on BIO 300 at Government Conference
Read More
09.25.18
Humanetics Corporation Presents Data on BIO 300 at Radiation Research Society Annual Meeting
Read More
07.17.18
Humanetics Corporation Awarded Patent for Oral Drug to Protect Warfighters and First Responders from Radiation Injury
Read More
04.12.18
Humanetics Corporation Awarded Federal Contract to Develop New Radiation Countermeasure to Protect the Lungs
Read More
02.12.18
Humanetics Corporation Presents at 2018 BIO CEO and Investor Conference
Read More
01.30.18
Humanetics Corporation Presents Data on Drug to Protect Cardiac Cells Against Toxicity From Space-Like Radiation
01.11.18
Vice Admiral Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Humanetics' Medical Advisory Board